Recent and Emerging Co-Infections in the Setting of ART: COVID-19 and MPOX

Constance A. Benson, MD

Professor of Medicine and Global Public Health University of California San Diego

1

2

Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:

Dr Benson has served on advisory and data safety monitoring boards for GlaxoSmithKline/ViiV Healthcare, received research grants awarded to her institution from Gilead Sciences, Inc., and serves as a consultant to NDA Partners, LLC. (Updated 12/12/22)

Slide 2

Learning Objectives


After attending this presentation, learners will be able to:

- Describe the approaches to outpatient treatment of COVID-19 in people with HIV
- Initiate SARS-CoV-2 vaccination recommendations for people with HIV
- Implement current treatment and vaccination recommendations for MPOX in people with HIV

Slide 3



4



5

Case 1

- 65 yo male presents with low-grade fever, cough, headache, and sore throat for 2 days
- Rapid COVID test is positive at home; rapid influenza negative
- HIV RNA < 20 c/ml
 - CD4 560 cells/ul
 - Smoker
- ARV Rx = Dolutegravir / lamivudine (fdc), rosuvastatin
- Oxygen saturation \simeq 94 95% on room air

6


Slide 6


ARS Question 1: How would you treat his SARS-CoV-2 infection?

- A. Initiate nirmatrelvir/ritonavir
- B. Administer bamlanivimab/etesevimab infusion
- C. Administer bebtelovimab infusion
- D. Administer remdesivir outpatient infusion (over 3 days)
- E. Initiate molnupiravir
- F. Initiate prednisone (40 mg daily)

Slide 7

7







Key Recommendations for COVID-19 and People With HIV

- People with HIV who develop COVID-19 should be treated according to current guidelines for management of COVID-19, regardless of CD4 cell count or viral suppression (evidence rating: Ala)
- People with HIV who develop mild-moderate COVID-19 and have CD4 cell counts less than 200/µL or without viral suppression should be treated with ritonavir-boosted nirmatrelvir (evidence rating: Alla).
 - · Drug-drug interactions should be taken into consideration
- People with HIV who recover from severe COVID-19 should be monitored for post-acute sequelae of SARS-CoV-2 ("long COVID") and ART should be optimized to the extent possible to further reduce inflammatory responses to COVID-19 and HIV (evidence rating: AllI)

Slide 10

10


Key Recommendations for COVID-19 and People With HIV

- Primary COVID-19 vaccination and vaccine boosting is recommended for all people with HIV (evidence rating: Ala). For those who have untreated HIV infection or a CD4 cell count less than 200/µL, the primary vaccination series should include at least 3 vaccine doses and vaccine booster doses (evidence rating: Alla)
- If circulating SARS-CoV-2 variants anticipated to be susceptible, preexposure prophylaxis with tixagevimab (300 mg) plus cligavimab (300 mg) to prevent COVID-19 is recommended for adults and adolescents who have <u>untreated</u> HIV infection or a CD4 cell count less than 200/µL or those not able to be fully vaccinated (evidence rating: BIII)
- Postexposure prophylaxis is not recommended for people with HIV (evidence rating: AIII). Currently available monoclonal antibody agents are not sufficiently effective against the predominant circulating variants and subvariants.


Slide 11

Why PWH May Have Worse COVID-19 Outcomes	
Immunodeficiency Patients with advanced HIV (low CD4 cell counts, untreated HIV) may have prolonged SARS CoV-2 replication	Comorbidities PWH have high rates of comorbidities that are also risk factors for severe COVID
	 Social determinants of health
Possibility of Worse COVID-19 Outcomes Highlights Importance o COVID-19 Vaccination and Treatmen in people with HIV	risk factors for worse COVID
Slide 12	Triant V and Gandhi R, CID 2021





13



14



Question

How do I treat new skin lesions and fever in the outpatient setting?

16

Case 2

- 30 yo Male presents with new lesions on his buttocks, groin, back, and face
- MSM; Febrile
- Several different sexual partners in the last 4 weeks
- HIV RNA 28,000 c/ml (off ARV now)
- CD4 count 250 cells/ul
- UDS + methamphetamine



Slide 17

Slide 16

17

ARS Question 2: In addition to STI screening and MPOX culture, which of the following would you do?

- A. Treat for molluscum contagiosum
- B. Start tecovirimat at this visit
- C. Wait for cultures, if positive for MPOX, start tecovirimat
- D. Would not Rx tecovirimat (not indicated in this setting)
- E. No specific MPOX treatment; instead administer JYNNEOS vaccine now

Slide 18


Key Recommendations for MPOX

- Coinfection with other STIs is frequent and should be screened for when MPOX is first recognized or suspected (evidence rating: AIII)
- Treatment recommendations are evolving, but those patients who are immunosuppressed or otherwise at high risk for progression or those with severe disease should receive oral or intravenous tecovirimat (evidence rating: BIII)
- For individuals with a known exposure, the JYNNEOS vaccine (smallpox and MPOX vaccine, live, nonreplicating [Bavarian Nordic]) should be administered to asymptomatic contacts ideally within 4 days but up to 14 days (evidence rating: AIII).

Slide 19

 Primary JYNNEOS vaccination with 2 doses given at least 28 days apart is recommended for individuals at high risk (evidence rating: AIII)

19





Severe MPOX in People with Advanced HIV




- 47 (82%) had HIV, only 4 (9%) on ART; CD4 count <50 in 72%
- 95% male; 68% non-Hispanic Black, 23% experiencing homelessness
- 93% received tecovirimat
 12 (21%) died
- MPOX cause or contributing factor in 5 deaths; additional 6 deaths under investigation



Emphasizes importance of testing people with MPXV infection for HIV and importance of diagnosing and treating all PWH





22

